Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-007 (govorestat) in pediatric classic galactosemia
2023-001104-33Phase 3
- Sponsor
- Applied Therapeutics, Inc.
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of govorestat in Classical Galactosemia (CG), sponsored by Applied Therapeutics, Inc. Primary endpoint: Composite clinical benefit across 4 domains.
02
Drugs
govorestat
03
Conditions
Classical Galactosemia (CG)
Beyond the preview
Go deeper on 2023-001104-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-001104-33.